Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients

Acta Neurologica Scandinavica

Volumn 117, Issue 4, 2008, Pages 250-254

  Sztriha, L K ^a   Sas, K ^a   Seres, E ^a   Boda, K ^a   Lenti, L ^a   Csifcsak, G ^a   Kovacs, N ^a   Vecsei, L ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Aspirin resistance; Cerebrovascular diseases; Neuropharmacology; Strokes; Transient ischemic attack; Treatment; Vascular risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; AUTOMATIC DATA PROCESSING; BRAIN ISCHEMIA; DRUG RESISTANCE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 40549114259     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00937.x     Document Type: Article

References (14)

1. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 : 234S 264S.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
3. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006 367 : 606 17.
4. Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006 113 : 31 5.
5. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993 71 : 397 403.
6. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003 41 : 961 5.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 105 : 1650 5.
8. Born GUR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962 194 : 927 9.
9. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994 25 : 2331 6.
10. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005 36 : 276 80.
11. O'Donnell CJ, Larson MG, Feng D et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001 103 : 3051 6.
12. Faraday N, Yanek LR, Mathias R et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007 115 : 2490 6.
13. Patrono C, Rocca B. Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med 2007 4 : 42 50.
14. Johnson P, Rosewell M, James MA. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy? Cerebrovasc Dis 2007 23 : 156 61.